French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction 2010. FAST-MI 2010
- Michel Hanssen1,
- Yves Cottin2,
- Khalife Khalife3,
- Laure Hammer4,
- Patrick Goldstein5,
- Etienne Puymirat6,
- Geneviève Mulak7,
- Elodie Drouet8,
- Benoit Pace7,
- Eric Schultz7,
- Vincent Bataille9,
- Jean Ferrières9,
- Tabassome Simon10,
- Nicolas Danchin6,
- for the FAST-MI 2010 investigators
- 1Department of Cardiology, Centre hospitalier de Haguenau, Haguenau Cedex, France
- 2Department of Cardiology, Centre hospitalier universitaire de Dijon, Dijon, France
- 3Department of Cardiology, Centre hospitalier régional de Metz, Metz, France
- 4Department of Cardiology, Intensive Care Cardiology, Clinique Belledonne, Saint Martin d'Hères, France
- 5Emergency Department and SAMU, Centre hospitalier régional universitaire de Lille, and Université Lille II, France
- 6Department of Cardiology, Hôpital Européen Georges Pompidou, AP-HP, Paris and Université Paris Descartes, Paris, France
- 7Société Française de Cardiologie, Paris, France
- 8URC-EST, Hôpital St Antoine, AP-HP, Paris, France
- 9Department of Cardiology and INSERM 1027, Toulouse Rangueil University Hospital, Toulouse, France
- 10Department of Pharmacology, Hôpital St Antoine, AP-HP, Paris and Université Pierre et Marie Curie, Paris, France
- Correspondence to Professor Nicolas Danchin, Department of Cardiology, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France;
Contributors All authors have participated in the registry, and have contributed to the design, collection, analysis of the data, writing, or critical reviewing of the manuscript.
- Received 20 January 2012
- Revised 1 March 2012
- Accepted 2 March 2012
Aim of FAST-MI 2010 To gather data on characteristics, management and outcomes of patients hospitalised for acute myocardial infarction (AMI) at the end of 2010 in France.
Interventions To provide cardiologists and health authorities national and regional data on AMI management every 5 years.
Setting Metropolitan France. 213 academic (n=38), community (n=110), army hospitals (n=2), private clinics (n=63), representing 76% of centres treating AMI patients. Inclusion from 1 October 2010.
Population Consecutive patients included during 1 month, with a possible extension of recruitment up to one additional month (132 centres); 4169 patients included over the entire recruitment period, 3079 during the first 31 days; 249 additional patients declining participation (5.6%).
Startpoints Consecutive adults with ST-elevation and non-ST-elevation AMI with symptom onset ≤48 h. Patients with AMI following cardiovascular procedures excluded.
Data capture Web-based collection of 385 items (demographic, medical, biologic, management data) recorded online from source files by external research technicians; case-record forms with automatic quality checks. Centralised biology in voluntary centres to collect DNA samples and serum. Long-term follow-up organised centrally with interrogation of municipal registry offices, patients' physicians, and direct contact with the patients.
Data quality Data management in Toulouse University. Statistical analyses: Université Paris Descartes, Université de Toulouse, Université Pierre et Marie Curie-Paris 06, Paris.
Endpoints and linkages to other data In-hospital events; cardiovascular events, hospital admissions and mortality during follow-up. Linkage with Institute for National Statistics.
Access to data Available for research to any participating clinician upon request to executive committee ().
Funding MSD, Eli-Lilly, Daiichi Sankyo, AstraZeneca, GSK, Novartis, sanofi-aventis.
Disclosures MH: speaker and consulting fees: AstraZeneca, Daiichi-Sankyo, Eli-Lilly. YC: speaker and consulting fees: Boehringer-Ingelheim, MSD, Pfizer, Novartis, Servier. PG: speaker and consulting fees: Boeringer-Ingelheim, The Medicines Company, sanofi-aventis, BMS, AstraZeneca, Lilly Daiichi Sankyo JF: speaker fees: Astra Zeneca, Merck, Novartis, Servier. TS: research grants: Astra-Zeneca, Daiichi-Sankyo, Eli-Lilly, Glaxo-Smith-Kline, MSD, Novartis, Pfizer, sanofi-aventis, Servier; speaker and consulting fees: AstraZeneca, Bayer-Schering, Eli-Lilly, sanofi-aventis. ND: research grants: Astra-Zeneca, Daiichi-Sankyo, Eli-Lilly, Glaxo-Smith-Kline, MSD, Novartis, Pfizer, sanofi-aventis, Servier and The Medicines Company; advisory panels or lecture fees: Astra-Zeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Menarini, Merck-Serono, Novo-Nordisk, Servier, sanofi-aventis.
Competing interests None.
Ethics approval Ethics approval was approved by CPP St Louis hospital, Paris.
Provenance and peer review Not commissioned; externally peer reviewed.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.